TABLE 12.

Results of the selected studies examining oncolytic viruses in treating ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose	Results
Galanis et al. (Galanis et al., 2010)	2021	I	21	MV-CEA virus every 4 weeks for up to 6 cycles at seven different dose levels (103–109 TCID50)	Median survival was 12.15 (1.3–38.4 months), best objective response was dose-dependent disease stabilization was observed in 14 of 21 patients and with median duration of 92.5 days (54–277 days)
Cohn et al. (Cohn et al., 2017)	2017	II	108	Paclitaxel (80 mg/m2 intravenously days 1, 8, and 15 every 4 weeks) or the combination of paclitaxel (80 mg/m2 intravenously days 1, 8, and 15) plus reovirus 3 × 1010 TCID50/day intravenously on days 1–5, both every 4 weeks until disease progression or toxicity	Median PFS was 4.3 months for paclitaxel and 4.4 months for paclitaxel plus reovirus
ColoAd1-2001 (Moreno et al., 2021)	2021	I	38	Enadenotucirev iv. (1 × 1,012 viral particles; days 1, 3 and 5 every 28-day for two cycles) plus paclitaxel (80 mg/m2; days 9, 16 and 23 of each cycle)	4-month PFS rate for 20 patients who received intravenous enadenotucirev plus paclitaxel was 64% (median 6.2 months) and 63% of the patients experienced treatment-emergent adverse event - first of all neutropenia (21%)

MV-CEA, carcinoembryonic antigen-expressing oncolytic measles virus derivative; TCID, tissue culture infectious dose; PFS, progression-free survival.